Renaissance Technologies LLC decreased its stake in BioTime, Inc. (NYSEAMERICAN:BTX) by 81.2% during the second quarter, Holdings Channel reports. The institutional investor owned 145,600 shares of the biotechnology company’s stock after selling 630,800 shares during the quarter. Renaissance Technologies LLC’s holdings in BioTime were worth $300,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Bank of New York Mellon Corp boosted its position in BioTime by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock worth $1,534,000 after purchasing an additional 33,350 shares in the last quarter.

Separately, Zacks Investment Research upgraded BioTime from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Wednesday, August 8th.

Shares of BTX stock opened at $1.92 on Friday. BioTime, Inc. has a 12-month low of $1.80 and a 12-month high of $3.16.

BioTime (NYSEAMERICAN:BTX) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $0.98 million during the quarter, compared to the consensus estimate of $0.75 million.

COPYRIGHT VIOLATION WARNING: “Renaissance Technologies LLC Sells 630,800 Shares of BioTime, Inc. (BTX)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/11/10/renaissance-technologies-llc-sells-630800-shares-of-biotime-inc-btx.html.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Featured Article: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.